Skip to main content

Table 4 Incidence of adverse drug reactions caused by prophylactic trimethoprim–sulfamethoxazole

From: Pneumocystis pneumonia in patients with rheumatic diseases receiving prolonged, non-high-dose steroids—clinical implication of primary prophylaxis using trimethoprim–sulfamethoxazole

 

Number of casesa

Incidence rate (95% CI)b

Mild-to-moderate adverse drug reactions

11

30.7 (15.3–55.0)

 Anemia

1

2.8 (0.1–15.6)

 Thrombocytopenia

2

5.6 (0.7–20.2)

 LFT abnormality

3

8.4 (1.7–24.5)

 Skin rash

2

5.6 (0.7–20.2)

 Azotemia

1

2.8 (0.1–15.6)

 Othersc

2

5.6 (0.7–20.2)

Serious adverse drug reactionsd

1

2.8 (0.1–15.6)

 Pancytopeniad

1

2.8 (0.1–15.6)

 Stevens–Johnson syndrome

0

NA

  1. CI confidence interval, LFT liver function test, NA non-applicable
  2. aTotal observation period was 31.0 person-years for 45 episodes
  3. bRate per 100 person-years
  4. cIncluding headache (n = 1) and tingling sensation (n = 1)
  5. dOccurred in the non-high-risk subgroup